GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Curative Biosciences CBDX · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2017

Net income

−$53,195

FY2014FY2017

Free cash flow

−$12,797

FY2014FY2017

Shareholders' equity

−$630,800

FY2014FY2017

Income statement

Fiscal years

FY2017FY2016FY2015FY2014
Gross profit−$2,848−$2,848—−$53,152
Research and development—$50,000$50,000$50,000
Operating income−$53,200−$1.6m−$1.7m−$468,658
Net income−$53,195−$1.7m−$3.4m−$30.0m
Diluted earnings per share-0.00-0.08-0.17-1.50

Balance sheet

At each fiscal year end

FY2017FY2016FY2015FY2014
Total assets$2,265$5,113$9,962$15,651
Total liabilities$633,065$620,218$705,764$381,443
Debt$62,825$50,028$23,027$84,637
Shareholders' equity−$630,800−$615,105−$695,802−$365,792
Shares outstanding15m20m20m20m

Cash flow

Fiscal years

FY2017FY2016FY2015FY2014
Cash from operations−$12,797−$29,002−$65,350−$144,278
Free cash flow−$12,797−$29,002−$65,350−$144,278

Latest quarters

By quarter end

Mar 2018Dec 2017Sept 2017Jun 2017Mar 2017Dec 2016Sept 2016Jun 2016
Operating income−$31,982−$451,518−$16,701−$17,894−$4,000−$10,000−$20,000−$50,000
Net income−$31,982−$451,518−$16,701−$17,894−$4,000−$10,000−$20,000−$50,000
Diluted earnings per share-0.00-0.03-0.00-0.00-0.00———
Total assets$13,871$841$1,553$2,265$2,977——$10,000
Debt$156,453$111,441$80,468$62,825—$60,000$50,000$50,000
Shareholders' equity−$705,669−$673,687−$647,501−$630,800−$612,906−$610,000−$600,000−$620,000

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-51.6%-61.5%0.6%
Net income-87.9%-63.3%2.9%

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return100%-0%-25%900%-99%89%22%2760%2582%1716%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 100-to-1 reverse split · 28 Oct 2013
  • 50-to-1 reverse split · 1 Oct 2012
  • 70-to-1 reverse split · 19 Aug 2010

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.